Dr Ina Rudloff
- Senior Research Scientist, Interventional Immunology in Early Life Diseases
- ina.rudloff@hudson.org.au
Dr Ina Rudloff is a member of the Interventional Immunology in Early Life Diseases Research group in The Ritchie Centre.
Areas of interest
Bronchopulmonary dysplasia Lupus Necrotising enterocolitis (NEC) Preterm birth
Research group
Interventional Immunology in Early Life Diseases
Biography
Dr Ina Rudloff is a Senior Research Scientist at the Hudson Institute of Medical Research and an Adjunct Senior Research Fellow at Monash University. She obtained her PhD from Goethe University Frankfurt, Germany, supported by a competitive fellowship from the German Research Foundation (DFG), and joined the Interventional Immunology in Early Life Diseases research group at Hudson Institute in 2012.
Ina’s research focuses on understanding the molecular mechanisms regulating inflammation and exploring the therapeutic potential of endogenous immunoregulatory pathways. Her work encompasses a range of inflammatory conditions, including neonatal diseases (necrotising enterocolitis and bronchopulmonary dysplasia), autoimmune diseases (systemic lupus erythematosus) and viral infections.
She has made significant contributions to advancing our understanding of anti-inflammatory members of the interleukin-1 (IL-1) family, particularly IL-1 receptor antagonist (IL-1Ra), IL-37 and IL-38. These include contributions to the discovery of the IL-37 receptor complex, the characterisation of its anti-inflammatory signalling mechanisms and pioneering work on the immunomodulatory functions of IL-38. Her preclinical research on IL-1Ra also provided important evidence supporting the development of a clinical trial investigating the safety and therapeutic potential of anakinra in extremely premature infants.
Drawing on extensive experience in research leadership and industry partnerships, Ina has led research programmes in collaboration with major pharmaceutical and biotechnology companies, contributing to the development of novel cytokine-based therapeutics.
Her overarching goal is to translate fundamental discoveries in cytokine biology into innovative immunomodulatory treatments for severe inflammatory diseases.
Key areas of focus
- Inflammation
- Cytokine Biology
- Immunomodulation
- Drug Discovery & Translational Research
- Systemic lupus erythematosus (SLE)
- Necrotising enterocolitis (NEC)
- Bronchopulmonary dysplasia (BPD)